Monopar Therapeutics Shares Jump After First Patient Dosed in Cancer Therapy

MT Newswires Live12-07

Monopar Therapeutics (MNPR) shares were up more than 6% in recent Friday trading, a day after the company said the first cancer patient has been dosed in the company's therapeutic trial of MNPR-101-Lu.

The drug combines Monopar's antibody MNPR-101 with the therapeutic radioisotope lutetium-177, the company said.

MNPR-101 targets the urokinase plasminogen activator receptor, or uPAR, which is associated with highly malignant and metastatic cancers, including pancreatic, ovarian, triple negative breast, and colorectal cancers.

Monopar said it found MNPR-101-Lu intravenous infusion to be well-tolerated with no serious adverse reactions.

Price: 22.31, Change: +1.31, Percent Change: +6.24

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2489226333?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-07 03:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2489226333","market":"sh","top_or_hot":-1,"title":"Monopar Therapeutics Shares Jump After First Patient Dosed in Cancer Therapy","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/MNPR\">Monopar Therapeutics</a> (MNPR) shares were up more than 6% in recent Friday trading, a day after the company said the first cancer patient has been dosed in the company's therapeutic trial of MNPR-101-Lu.</p><p>The drug combines Monopar's antibody MNPR-101 with the therapeutic radioisotope lutetium-177, the company said.</p><p>MNPR-101 targets the urokinase plasminogen activator receptor, or uPAR, which is associated with highly malignant and metastatic cancers, including pancreatic, ovarian, triple negative breast, and colorectal cancers.</p><p>Monopar said it found MNPR-101-Lu intravenous infusion to be well-tolerated with no serious adverse reactions.</p><p>Price: 22.31, Change: +1.31, Percent Change: +6.24</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Monopar Therapeutics Shares Jump After First Patient Dosed in Cancer Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMonopar Therapeutics Shares Jump After First Patient Dosed in Cancer Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-07 03:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Monopar Therapeutics (MNPR) shares were up more than 6% in recent Friday trading, a day after the company said the first cancer patient has been dosed in the company's therapeutic trial of MNPR-101-Lu...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2489226333","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489226333","pubTimestamp":1733515055,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Monopar Therapeutics  shares were up more than 6% in recent Friday trading, a day after the company said the first cancer patient has been dosed in the company's therapeutic trial of MNPR-101-Lu.The drug combines Monopar's antibody MNPR-101 with the therapeutic radioisotope lutetium-177, the company said.MNPR-101 targets the urokinase plasminogen activator receptor, or uPAR, which is associated with highly malignant and metastatic cancers, including pancreatic, ovarian, triple negative breast, and colorectal cancers.Monopar said it found MNPR-101-Lu intravenous infusion to be well-tolerated with no serious adverse reactions.Price: 22.31, Change: +1.31, Percent Change: +6.24","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MNPR":"Monopar Therapeutics"},"translate_title":"第一位患者接受癌症治疗后，Monopar Therapeutics股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNPR":1},"content_text":"Monopar Therapeutics (MNPR) shares were up more than 6% in recent Friday trading, a day after the company said the first cancer patient has been dosed in the company's therapeutic trial of MNPR-101-Lu.The drug combines Monopar's antibody MNPR-101 with the therapeutic radioisotope lutetium-177, the company said.MNPR-101 targets the urokinase plasminogen activator receptor, or uPAR, which is associated with highly malignant and metastatic cancers, including pancreatic, ovarian, triple negative breast, and colorectal cancers.Monopar said it found MNPR-101-Lu intravenous infusion to be well-tolerated with no serious adverse reactions.Price: 22.31, Change: +1.31, Percent Change: +6.24","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489226333"}